257 related articles for article (PubMed ID: 32272775)
21. The prognosis of TP53 and EGFR co-mutation in patients with advanced lung adenocarcinoma and intracranial metastasis treated with EGFR-TKIs.
Gu W; Liu P; Tang J; Lai J; Wang S; Zhang J; Xu J; Deng J; Yu F; Shi C; Qiu F
Front Oncol; 2023; 13():1288468. PubMed ID: 38375203
[TBL] [Abstract][Full Text] [Related]
22. Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations.
Canale M; Petracci E; Cravero P; Mariotti M; Minuti G; Metro G; Ludovini V; Baglivo S; Puccetti M; Dubini A; Martinelli G; Delmonte A; Crinò L; Ulivi P
Transl Oncol; 2022 Sep; 23():101471. PubMed ID: 35779323
[TBL] [Abstract][Full Text] [Related]
23.
Roeper J; Christopoulos P; Falk M; Heukamp LC; Tiemann M; Stenzinger A; Thomas M; Griesinger F
Transl Lung Cancer Res; 2022 Jan; 11(1):4-13. PubMed ID: 35242623
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic Review and Meta-analysis.
Yi XF; Song J; Gao RL; Sun L; Wu ZX; Zhang SL; Huang LT; Ma JT; Han CB
Front Oncol; 2022; 12():863666. PubMed ID: 35785185
[TBL] [Abstract][Full Text] [Related]
25. Evaluate the Prognosis of
Cao J; J Gu J; Liang Y; Wang B
Technol Cancer Res Treat; 2022; 21():15330338221138213. PubMed ID: 36524293
[No Abstract] [Full Text] [Related]
26. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.
Liu HL; Han G; Peng M; Weng YM; Yuan JP; Yang GF; Yu JM; Song QB
J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):864-872. PubMed ID: 29270745
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non-small-cell lung cancer with an EGFR/TP53 co-mutation.
Shang K; Huang H; Xu Y; Liu Y; Lu Z; Chen L
BMC Cancer; 2022 Dec; 22(1):1295. PubMed ID: 36503478
[TBL] [Abstract][Full Text] [Related]
28. Effects of concurrent TP53 mutations on the efficacy and prognosis of targeted therapy for advanced EGFR mutant lung adenocarcinoma.
Qian H; Hou C; Zhang Y; Ji S; Zhong C; Li J; Zhang Q; Huang J; Li C; ChengJi
Cancer Genet; 2023 Nov; 278-279():62-70. PubMed ID: 37672936
[TBL] [Abstract][Full Text] [Related]
29. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
[TBL] [Abstract][Full Text] [Related]
30. Aumolertinib in NSCLC with leptomeningeal involvement, harbouring concurrent
Qin Z; Zhang H; Yan P; Yu L; Hong C; Calvetti L; Passaro A; Araujo A; Chen Y
J Thorac Dis; 2023 Jul; 15(7):4016-4026. PubMed ID: 37559636
[TBL] [Abstract][Full Text] [Related]
31. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.
van Veggel B; Madeira R Santos JFV; Hashemi SMS; Paats MS; Monkhorst K; Heideman DAM; Groves M; Radonic T; Smit EF; Schuuring E; van der Wekken AJ; de Langen AJ
Lung Cancer; 2020 Mar; 141():9-13. PubMed ID: 31926441
[TBL] [Abstract][Full Text] [Related]
32. Disease monitoring of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA.
Li Y; Xu Z; Wang S; Zhu Y; Ma D; Mu Y; Ying J; Li J; Xing P
Thorac Cancer; 2022 Aug; 13(15):2201-2209. PubMed ID: 35778830
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive characterization and clinical impact of concomitant genomic alterations in EGFR-mutant NSCLCs treated with EGFR kinase inhibitors.
Cheng Y; Ma L; Liu Y; Zhu J; Xin Y; Liu X; Wang Y; Zhang T; Yang C; Wang S; Cui H; Zhang L; Dai J; Shao L; Lin J; Ye J; Liu H
Lung Cancer; 2020 Jul; 145():63-70. PubMed ID: 32408134
[TBL] [Abstract][Full Text] [Related]
34. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
[TBL] [Abstract][Full Text] [Related]
35. The efficacy of immune checkpoint inhibitors in advanced
Hu J; Huang D; Wang Y; Li D; Yang X; Fu Y; Du N; Zhao Y; Li X; Ma J; Hu Y
Front Immunol; 2022; 13():975246. PubMed ID: 36159795
[TBL] [Abstract][Full Text] [Related]
36. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
VanderLaan PA; Rangachari D; Mockus SM; Spotlow V; Reddi HV; Malcolm J; Huberman MS; Joseph LJ; Kobayashi SS; Costa DB
Lung Cancer; 2017 Apr; 106():17-21. PubMed ID: 28285689
[TBL] [Abstract][Full Text] [Related]
37. Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study.
Kim TH; Choi JH; Ahn MS; Lee HW; Kang SY; Choi YW; Koh YW; Sheen SS
BMC Cancer; 2024 Jan; 24(1):70. PubMed ID: 38216948
[TBL] [Abstract][Full Text] [Related]
38. First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution's clinical practice experience.
Yu X; Zhang X; Zhang Z; Lin Y; Wen Y; Chen Y; Wang W; Zhang L
Cancer Commun (Lond); 2018 Jul; 38(1):51. PubMed ID: 30055651
[TBL] [Abstract][Full Text] [Related]
39. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan.
Chang JW; Huang CY; Fang YF; Chang CF; Yang CT; Kuo CS; Hsu PC; Wu CE
Thorac Cancer; 2023 Jan; 14(1):12-23. PubMed ID: 36424878
[TBL] [Abstract][Full Text] [Related]
40. Concurrent TP53 mutations predict a poor prognosis of EGFR-mutant NSCLCs treated with TKIs: An updated systematic review and meta-analysis.
Lan B; Zhao N; Du K; Leng B
Oncol Lett; 2022 Nov; 24(5):384. PubMed ID: 36238360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]